Abstract
Frailty has emerged as one of the most relevant clinical syndromes in older patients. This term relates to the loss of functional reserve that can occur in some older people following exposure to one or more low-intensity stressors placing them at high risk for developing a number of adverse outcomes such as disability, falls, hospitalization and death. Frailty is the outcome of two combined effects: the ageing process and other superimposed injuries like chronic disease or, indeed, psychological and social stressors. The mechanisms leading to frailty typically involve several systems: mainly hormones, oxidative stress, inflammation, immunity, and vascular system. One of the most outstanding pillars of the frailty syndrome is the loss of muscle quantity and function, referred to as sarcopenia. The main bulk of experimental pharmacological interventions addressing the clinical problem of frailty have been focused on the use of hormones, as replacement therapy in subjects with low or normal circulating basal levels of the hormone. Results have been disappointing, except for the case of testosterone that have shown some benefits. The effectiveness of other potential therapeutic interventions (antioxidants, anti-inflammatory agents, nutritional supplements) appears to be limited or has not been explored in detail until now. In conclusion, there is an available path to prevent the development of disability in older people through the treatment of frailty, its main risk factor. Aditional research and further experimental testing will help to identify new targets and help to make this journey successful.
Keywords: Frailty, concept, pathophysiology, pharmacological targets, treatment, RCTs.
Current Pharmaceutical Design
Title:Pharmaceutical Interventions for Frailty and Sarcopenia
Volume: 20 Issue: 18
Author(s): Olga Laosa, Cristina Alonso, Marta Castro and Leocadio Rodriguez-Manas
Affiliation:
Keywords: Frailty, concept, pathophysiology, pharmacological targets, treatment, RCTs.
Abstract: Frailty has emerged as one of the most relevant clinical syndromes in older patients. This term relates to the loss of functional reserve that can occur in some older people following exposure to one or more low-intensity stressors placing them at high risk for developing a number of adverse outcomes such as disability, falls, hospitalization and death. Frailty is the outcome of two combined effects: the ageing process and other superimposed injuries like chronic disease or, indeed, psychological and social stressors. The mechanisms leading to frailty typically involve several systems: mainly hormones, oxidative stress, inflammation, immunity, and vascular system. One of the most outstanding pillars of the frailty syndrome is the loss of muscle quantity and function, referred to as sarcopenia. The main bulk of experimental pharmacological interventions addressing the clinical problem of frailty have been focused on the use of hormones, as replacement therapy in subjects with low or normal circulating basal levels of the hormone. Results have been disappointing, except for the case of testosterone that have shown some benefits. The effectiveness of other potential therapeutic interventions (antioxidants, anti-inflammatory agents, nutritional supplements) appears to be limited or has not been explored in detail until now. In conclusion, there is an available path to prevent the development of disability in older people through the treatment of frailty, its main risk factor. Aditional research and further experimental testing will help to identify new targets and help to make this journey successful.
Export Options
About this article
Cite this article as:
Laosa Olga, Alonso Cristina, Castro Marta and Rodriguez-Manas Leocadio, Pharmaceutical Interventions for Frailty and Sarcopenia, Current Pharmaceutical Design 2014; 20 (18) . https://dx.doi.org/10.2174/13816128113196660705
DOI https://dx.doi.org/10.2174/13816128113196660705 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mast Cells in Allergic and Inflammatory Diseases
Current Pharmaceutical Design Natural Products to Anti-trypanosomal Drugs: An Overview of New Drug Prototypes for American Trypanosomiasis
Cardiovascular & Hematological Agents in Medicinal Chemistry A More Accurate Approach to Molecular Genetics Analysis in Vascular Disease
Cardiovascular & Hematological Disorders-Drug Targets PET Molecular Imaging of Hypoxia in Ischemic Stroke: An Update
Current Vascular Pharmacology Developments in Non-Surgical Therapies for Abdominal Aortic Aneurysm
Current Vascular Pharmacology Gene Therapy Targeting Inflammation in Atherosclerosis
Current Pharmaceutical Design Renal Artery Stenosis: Current Perspectives on Imaging and Endovascular Management
Current Hypertension Reviews Diabetic CVD – Soluble Epoxide Hydrolase as A Target
Cardiovascular & Hematological Agents in Medicinal Chemistry Indications for Surgery and Operative Techniques in Infective Endocarditis in the Present Day
Infectious Disorders - Drug Targets MicroRNAs in Peripheral Artery Disease
Current Topics in Medicinal Chemistry Immunosuppressive Treatments in Acute Myocardial Infarction and Stroke
Current Pharmaceutical Biotechnology Clinical Applications of Transcranial Doppler Sonography
Reviews on Recent Clinical Trials Renal Artery Stenting: Efficacy and Complications
Current Hypertension Reviews Sestrins: A New Kid for Stroke Treatment?
Current Drug Delivery Boosting Interleukin-10 Production: Therapeutic Effects and Mechanisms
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Hereditary Haemorrhagic Teleangiectasia: Diagnostic Imaging of Visceral Involvement
Current Pharmaceutical Design Progress in the Development of Matrix Metalloproteinase Inhibitors
Current Medicinal Chemistry Nanoparticle Based Delivery of Protease Inhibitors to Cancer Cells
Current Medicinal Chemistry Significant Correlation between Cystatin C, Cerebral Infarction, and Potential Biomarker for Increased Risk of Stroke
Current Neurovascular Research Epigenetics in the Cerebrovascular System: Changing the Code without Altering the Sequence
Current Neurovascular Research